Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Atrial Fibrillation and Percutaneous Coronary Intervention

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bicuspid Aortic Valve Anatomy and Relationship With Devices: The BAVARD Multicenter Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Infective Endocarditis Following Transcatheter Aortic Valve Replacement: Comparison of Balloon- Versus Self-Expandable Valves

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Lorenz Räber
  • Roland Klingenberg
  • Dik Heg
  • Henning Kelbæk
  • Marco Roffi
  • David Tüller
  • Andreas Baumbach
  • Thomas Zanchin
  • David Carballo
  • Miodrag Ostojic
  • Giulio G Stefanini
  • Nicolas Rodondi
  • Clemens von Birgelen
  • Aris Moschovitis
  • Thomas Engstrøm
  • Baris Gencer
  • Reto Auer
  • Bernhard Meier
  • Francois Mach
  • Thomas F Lüscher
  • Peter Jüni
  • Christian M Matter
  • Stephan Windecker
  • COMFORTABLE and SPUM-ACS Trial Investigators
Vis graf over relationer

OBJECTIVES: The aim of this study was to assess the safety of the concurrent administration of a clopidogrel and prasugrel loading dose in patients undergoing primary percutaneous coronary intervention.

BACKGROUND: Prasugrel is one of the preferred P2Y12 platelet receptor antagonists for ST-segment elevation myocardial infarction patients. The use of prasugrel was evaluated clinically in clopidogrel-naive patients.

METHODS: Between September 2009 and October 2012, a total of 2,023 STEMI patients were enrolled in the COMFORTABLE (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction [STEMI]) and the SPUM-ACS (Inflammation and Acute Coronary Syndromes) studies. Patients receiving a prasugrel loading dose were divided into 2 groups: 1) clopidogrel and a subsequent prasugrel loading dose; and 2) a prasugrel loading dose. The primary safety endpoint was Bleeding Academic Research Consortium types 3 to 5 bleeding in hospital at 30 days.

RESULTS: Of 2,023 patients undergoing primary percutaneous coronary intervention, 427 (21.1%) received clopidogrel and a subsequent prasugrel loading dose, 447 (22.1%) received a prasugrel loading dose alone, and the remaining received clopidogrel only. At 30 days, the primary safety endpoint was observed in 1.9% of those receiving clopidogrel and a subsequent prasugrel loading dose and 3.4% of those receiving a prasugrel loading dose alone (adjusted hazard ratio [HR]: 0.57; 95% confidence interval [CI]: 0.25 to 1.30, p = 0.18). The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly) bleeding score tended to be higher in prasugrel-treated patients (p = 0.076). The primary safety endpoint results, however, remained unchanged after adjustment for these differences (clopidogrel and a subsequent prasugrel loading dose vs. prasugrel only; HR: 0.54 [95% CI: 0.23 to 1.27], p = 0.16). No differences in the composite of cardiac death, myocardial infarction, or stroke were observed at 30 days (adjusted HR: 0.66, 95% CI: 0.27 to 1.62, p = 0.36).

CONCLUSIONS: This observational, nonrandomized study of ST-segment elevation myocardial infarction patients suggests that the administration of a loading dose of prasugrel in patients pre-treated with a loading dose of clopidogrel is not associated with an excess of major bleeding events. (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction [STEMI] [COMFORTABLE]; NCT00962416; and Inflammation and Acute Coronary Syndromes [SPUM-ACS]; NCT01000701).

OriginalsprogEngelsk
TidsskriftJACC. Cardiovascular interventions
Vol/bind8
Udgave nummer8
Sider (fra-til)1064-74
Antal sider11
ISSN1941-7640
DOI
StatusUdgivet - jul. 2015

ID: 46197439